Lazzat Zhussupbekova

Dr. Lazzat Zhussupbekova

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
Dinara NurkinaDinara Nurkina
Dinara Nurkina
GZGyulnar Zhussupova
Gyulnar Zhussupova
ASAliya Smagulova
Aliya Smagulova
VRVenera Rakhmetova
Venera Rakhmetova
IKIlya Kukes
Ilya Kukes
Cardiovascular disease is a major cause of death worldwide and a global socio-economic problem. To date, there are numerous studies focused on finding new biomarkers of cardiovascular diseases. High-technological methods such as mass spectrometry (MS), high-performance liquid chromatography (HPLC), and nuclear magnetic resonance (NMR) spectroscopy enable us to record thousands of metabolites of organs and tissues. Studying organisms at a molecular level contributes to an in-depth understanding of preclinical conditions of various diseases. Metabolomics reflects the dynamics of metabolism distribution, including environmental influences, allowing us to create a metabolic profile of the patient. The aim of this review was to analyze current data on metabolomic and proteomic biomarkers in the diagnosis of cardiovascular diseases. The search databases were used to select studies on the potential clinical and diagnostic application of proteomic and metabolomic markers in cardiology. The selected sources were subjected to qualitative and thematic analysis. All biomarkers were grouped according to the pathophysiological process (inflammation, blood coagulation and lipid metabolism disorders, myocardial necrosis, etc.). The association of changes in metabolomic and proteomic profiles with the activation of pathogenic processes in the cardiovascular system was demonstrated. The use of these multivariate markers, individually or in combination, will increase the accuracy of early diagnosis and the effectiveness of treatment. This article also highlights the limitations of the method and possible ways to solve them.

26 June 2023 in Digital Diagnostics
Verified
Journal Article
Open access
PDF file
ETElvira Zh. Tanirkhanova
Elvira Zh. Tanirkhanova
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
DTDuman K. Turebekov
Duman K. Turebekov
BZBayana K. Zhakeyeva
Bayana K. Zhakeyeva
TBTamilla T. Baimukanova
Tamilla T. Baimukanova
ЖКЖакеева Баяна Каирбековна
Жакеева Баяна Каирбековна
BACKGROUND: In recent years, an increasing tendency of oncopathology in patients with chronic kidney disease (CKD) was observed. Clinical data demonstrate an increased risk of malignization in patients with decreased renal function. The cohort study (2022) reported a cumulative incidence of cancer in nephrology patients ranging from 10.8% to 15.3%. A high percentage of stage IV cancers were detected in patients with CKD at the time of diagnosis. In 2022, the American Association for Cancer Research published the results of a Mendelian Randomization Study examining the causal relationship between CKD and the risk of developing 19 local cancers, including renal cell cancer, cervical cancer, leukemia, and colorectal cancer. Several studies found a direct correlation between a decreased glomerular filtration rate and the development of oncopathologies. Therefore, cancer awareness is important in the management of patients with CKD. In patients with end-stage chronic renal disease (ESRD) who are on hemodialysis, X-ray diagnosis with iodine-containing radiopaque agents is possible without additional risk of kidney damage. AIM: To demonstratу the role of computed tomography (CT) in the diagnosis of oncopathology in a patient with CKD to attract the attention of physicians to the importance of using advanced diagnostic techniques in patients with CKD. METHODS: A clinical case of a 32-year-old patient M. who was hospitalized in the Therapeutic Department of Multidisciplinary City Hospital No. 2 in Astana was presented. RESULTS: A patient with ESRD resulting from chronic glomerulonephritis in a hypertensive form complained of dyspnea at rest, cough with difficult sputum, right thoracic pain, general weakness, and weight loss of 8 kg in 1 month. Past medical history showed that the patient was on alternate program hemodialysis for 4 years. Deterioration occurred within 3 months. The patient was examined at the place of residence. CT scan showed signs of tuberculosis of the upper right lobe (?) and lymphadenopathy of intrathoracic and axillary lymph nodes. A neoplasm was not excluded. The patient was consulted by a phthisiatrician, GeneXpert sputum was performed, and tuberculosis was excluded. In dynamics, ultrasound was conducted due to increasing dyspnea. Fluid accumulation in the pericardial and pleural cavities was detected. A pulmonologist assessed the situation as uremic pericarditis, pleurisy on the right side, and right-sided pneumonia in the upper lobe of unclear genesis. Antibacterial therapy was prescribed. Due to a significant deterioration of the condition, the patient went to the city hospital. At admission, respiratory failure, pain syndrome in the chest area, and marked asthenization up to cachexia were observed. Ultrasound of pleural cavities showed free fluid in the pleural cavity on the right (770 ml) and left (110 ml), whereas abdominal ultrasound revealed cavernous hemangiomas of the liver (?), echogenic suspension of the gallbladder, and splenomegaly. Echocardiography showed diffuse hypokinesis of all left ventricular walls. Grade 12 pulmonary hypertension was detected. Systolic function of the left ventricle was moderately decreased. Effusion in the pericardial cavity in the volume of 430 ml and congestion in the inferior vena cava were found. A patient with ESRD was on program hemodialysis for 4 years, which allowed the use of contrast-enhanced X-ray imaging techniques without the risk of additional renal damage. Contrast-enhanced chest CT showed pronounced right-sided pleurisy. Given the presence of foci of contrast agent accumulation in the structure of the parietal pleura, malignancy was not excluded (mesothelioma?). Indolent left-sided pleurisy, segmental and subsegmental compression atelectasis of the right lung, distinct edema and thickening of interlobular septa of both lungs, and single dense foci of I/II, III segments of the left lung up to 4.2 mm in diameter were detected. In addition, chronic bronchitis, pericarditis, and lymphadenopathy of subclavian, intrathoracic, and axillary lymph nodes up to 15.0 mm in diameter (malignancy not excluded) were revealed. Osteosclerosis foci of the Th3 vertebral body measuring 4.75.1 mm was observed. Contrast-enhanced abdominal and retroperineal CT scan showed a focal mass of the IVa segment of the liver measuring 17.315.916.4 mm (malignancy not excluded), chronic calculous cholecystitis, chronic pancreatitis, lymphadenopathy of intra-abdominal para-aortic and mesenteric lymph nodes up to 18.0 mm in size (malignancy not excluded), reduced size of both kidneys (contracted kidneys), and a cystic mass in the left ovary measuring 39.442.034.5 mm (35 HU). Patient was consulted by an oncologist: pleural mesothelioma? Metastasis in the liver? Consultation with a thoracic surgeon to decide on morphological verification was recommended. A biopsy was planned at the place of residence; however, morphological verification of oncopathology was not performed due to the patients lethal outcome. CONCLUSIONS: This clinical case of a patient with ESRD on hemodialysis demonstrates the importance of contrast-enhanced CT to diagnose oncopathology.

4 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
ABAlina Bulatova
Alina Bulatova
Dinara NurkinaDinara Nurkina
Dinara Nurkina
KKKlara Kurmangaliyeva
Klara Kurmangaliyeva
VRVenera Rakhmetova
Venera Rakhmetova
EAElmira Akhmedyarova
Elmira Akhmedyarova
Over the past decade, the growth of Helicobacter pylori antibiotic resistance has had an increasingly significant impact on the choice of eradication therapy regimens, significantly limiting the number of effective treatment options. The Maastricht VI guidelines consider the use of probiotics as one way to optimise therapy and increase the likelihood of successful eradication. In this regard, the study of the possible mechanisms of action of probiotic preparations on antibiotic-resistant strains of H. pylori, as well as their possible role in preventing the development of resistance, is of considerable interest and may contribute to improving the quality of eradication therapy in the near future. The aim of the study is to determine the role of probiotics in modifying the microbiota during and after eradication therapy, as well as to assess their potential impact on the development of antibiotic resistance. A search for scientific publications was conducted in international and national bibliographic databases: PubMed, Embase, Scopus, Web of Science Core Collection, Google Scholar, and eLIBRARY.ru. The search was conducted in English, Russian, and Kazakh for the period from 26 April 2015 to 14 July 2025. The review includes 41 publications. Eradication therapy has a pronounced negative effect on the intestinal microbiota, leading to disruption of its composition and the development of side effects that reduce treatment tolerability. A number of studies in recent years have demonstrated a link between antibiotic therapy and the development of antibiotic resistance caused by genetic rearrangements and mutations in the gut microbiota genome. As an additional approach to correcting these adverse effects, special attention is paid to the use of probiotics. According to the research results, probiotic preparations help reduce the frequency of side effects of eradication therapy and may increase its effectiveness against antibiotic-resistant strains of H. pylori. The use of probiotic preparations in the treatment of resistant strains of Helicobacter pylori is a promising direction that opens up new opportunities for optimising eradication regimens. However, this approach requires further clinical and experimental studies to confirm its effectiveness and form reasonable prognostic conclusions.

1 January 2023
Verified
Journal Article
Closed access
Dinara NurkinaDinara Nurkina
Dinara Nurkina
MBM Baimuratova
M Baimuratova
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
AKA Kodaspayev
A Kodaspayev
SAS Alimbayeva
S Alimbayeva

9 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
DNDildora Nasredinova
Dildora Nasredinova
NNNargiza Nurillaeva
Nargiza Nurillaeva
NKNargiza Kadirova
Nargiza Kadirova
AMAziz Mominov
Aziz Mominov
SKShoxista Kurbonova
Shoxista Kurbonova
This study aimed to examine the distribution of allele and genotype frequencies of the β-fibrinogen -455G/A polymorphism among patients with ischemic heart disease (IHD) and to evaluate fibrinogen levels according to genotype. Materials and methods: A total of 135 patients with primarily stable angina pectoris were included, comprising 57 men and 78 women, hospitalised in the First Cardiology Department of the Multidisciplinary Clinic at Tashkent Medical University. The mean age was 58.0 ± 1.2 years (range: 42–66 years). The control group consisted of 40 apparently healthy individuals. Results: In the main group, genotype frequencies were G/G – 53.3%, G/A – 22.2%, and A/A – 24.4%. In the control group, the respective frequencies were 57.5%, 22.5%, and 20.0%. The lowest fibrinogen levels were found in G/G genotype carriers, while the highest were observed in A/A genotype carriers. Conclusion: Although allele frequencies were similar between groups, a marked genotype-dependent effect on fibrinogen levels was identified. These findings align with published evidence that the A allele is associated with increased fibrinogen synthesis and a more prothrombotic phenotype.

4 November 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
YOYelvira Omralina
Yelvira Omralina
Aigyul IzhanovaAigyul Izhanova
Aigyul Izhanova
ABAlina Bulatova
Alina Bulatova
VRVenera Rakhmetova
Venera Rakhmetova
Kassymzhomart ZholamanovKassymzhomart Zholamanov
Kassymzhomart Zholamanov
The issue of early cancer diagnosis today is characterized by late symptom manifestation, difficulties in timely performing diagnostic procedures, and a lack of biomarkers that fully meet the criteria for sensitivity and specificity. An expanded search for novel diagnostic methods currently shows promise regarding the use of altered protein glycosylation patterns. This assumption is grounded in the ability of post-translational modifications, including changes in glycoprotein profiles and glycan structures, to serve as a signal of alterations at the level of synthetic processes. Tumor-associated glycan structures are released into the bloodstream, creating an opportunity for their detection using minimally invasive diagnostic methods. This article summarizes current data on the use of glycan signatures as cancer biomarkers for gastrointestinal and hepatopancreatic systems. The study utilized methodological discoveries in the fields of glycoproteomics and glycomics as informational material, actively integrating modern branches of omics technologies. Mass spectrometry and analytical methods made it possible to identify the most informative glycoproteomic and glycan biomarkers, the diagnostic efficacy of which was evaluated on internal and external validation cohorts. Analysis of the obtained data was performed with consideration of the limitations of the included studies, including small sample sizes, cohort heterogeneity, and potential publication bias. To enhance informativeness by developing new validation panels for early cancer detection, research recommendations for conducting new prospective studies are provided at the end of the review.